Ascelia Pharma AB (publ)

OM:ACE Stock Report

Market Cap: SEK 295.0m

Ascelia Pharma Valuation

Is ACE undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ACE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
SEK 47.29
Fair Value
93.5% undervalued intrinsic discount
3
Number of Analysts

Below Fair Value: ACE (SEK3.07) is trading below our estimate of fair value (SEK47.29)

Significantly Below Fair Value: ACE is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ACE?

Key metric: As ACE is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for ACE. This is calculated by dividing ACE's market cap by their current book value.
What is ACE's PB Ratio?
PB Ratio3.7x
BookSEK 78.94m
Market CapSEK 295.05m

Price to Book Ratio vs Peers

How does ACE's PB Ratio compare to its peers?

The above table shows the PB ratio for ACE vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average13x
ISOFOL Isofol Medical
3.7xn/aSEK 287.5m
ONCO Oncopeptides
6x45.6%SEK 323.6m
LIPUM Lipum
15.4x71.5%SEK 339.4m
CURAS Curasight
27.1xn/aDKK 171.7m
ACE Ascelia Pharma
3.7x66.9%SEK 295.0m

Price-To-Book vs Peers: ACE is good value based on its Price-To-Book Ratio (3.7x) compared to the peer average (13x).

Price to Book Ratio vs Industry

How does ACE's PB Ratio compare vs other companies in the SE Biotechs Industry?

7 CompaniesPrice / BookEstimated GrowthMarket Cap
TOL Toleranzia
0.5xn/aUS$8.72m
SPERM Spermosens
0.5xn/aUS$1.23m
APTA Aptahem
0.1xn/aUS$799.34k
QUIA Quia Pharma
0.4xn/aUS$681.02k
ACE 3.7xIndustry Avg. 2.4xNo. of Companies11PB0246810+
7 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: ACE is expensive based on its Price-To-Book Ratio (3.7x) compared to the Swedish Biotechs industry average (2.4x).

Price to Book Ratio vs Fair Ratio

What is ACE's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ACE PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio3.7x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate ACE's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst ACE forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentSEK 3.07
SEK 7.68
+150.3%
21.3%SEK 10.00SEK 6.50n/a3
Mar ’26SEK 3.48
SEK 7.68
+120.8%
21.3%SEK 10.00SEK 6.50n/a3
Feb ’26SEK 2.92
SEK 8.25
+183.0%
21.2%SEK 10.00SEK 6.50n/a2
Jan ’26SEK 2.92
SEK 8.25
+182.5%
21.2%SEK 10.00SEK 6.50n/a2
Dec ’25SEK 2.90
SEK 8.25
+184.5%
21.2%SEK 10.00SEK 6.50n/a2
Nov ’25SEK 2.18
SEK 9.00
+313.8%
33.3%SEK 12.00SEK 6.00n/a2
Oct ’25SEK 2.30
SEK 9.00
+292.2%
33.3%SEK 12.00SEK 6.00n/a2
Sep ’25SEK 2.20
SEK 14.75
+570.5%
18.6%SEK 17.50SEK 12.00n/a2
Aug ’25SEK 4.37
SEK 17.25
+295.2%
1.4%SEK 17.50SEK 17.00n/a2
Jul ’25SEK 8.40
SEK 17.25
+105.4%
1.4%SEK 17.50SEK 17.00n/a2
Jun ’25SEK 10.52
SEK 17.25
+64.0%
1.4%SEK 17.50SEK 17.00n/a2
May ’25SEK 10.58
SEK 9.75
-7.8%
23.1%SEK 12.00SEK 7.50n/a2
Apr ’25SEK 9.21
SEK 9.75
+5.9%
23.1%SEK 12.00SEK 7.50n/a2
Mar ’25SEK 7.74
SEK 9.75
+26.0%
23.1%SEK 12.00SEK 7.50SEK 3.482
Jan ’25SEK 3.37
SEK 19.50
+478.6%
59.0%SEK 31.00SEK 8.00SEK 2.922
Dec ’24SEK 2.75
SEK 19.50
+609.1%
59.0%SEK 31.00SEK 8.00SEK 2.902
Nov ’24SEK 2.99
SEK 20.50
+585.6%
51.2%SEK 31.00SEK 10.00SEK 2.182
Oct ’24SEK 3.92
SEK 20.50
+423.0%
51.2%SEK 31.00SEK 10.00SEK 2.302
Sep ’24SEK 4.02
SEK 21.00
+422.4%
47.6%SEK 31.00SEK 11.00SEK 2.202
Jul ’24SEK 16.78
SEK 48.00
+186.1%
35.4%SEK 65.00SEK 31.00SEK 8.402
Jun ’24SEK 16.42
SEK 48.00
+192.3%
35.4%SEK 65.00SEK 31.00SEK 10.522
May ’24SEK 14.22
SEK 48.00
+237.6%
35.4%SEK 65.00SEK 31.00SEK 10.582
Apr ’24SEK 14.80
SEK 48.00
+224.3%
35.4%SEK 65.00SEK 31.00SEK 9.212
Mar ’24SEK 16.30
SEK 48.00
+194.5%
35.4%SEK 65.00SEK 31.00SEK 7.742
Analyst Price Target
Consensus Narrative from 3 Analysts
SEK 7.68
Fair Value
60.0% undervalued intrinsic discount
3
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/23 00:35
End of Day Share Price 2025/03/21 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Ascelia Pharma AB (publ) is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ludvig SvenssonCarnegie Commissioned Research
Lars HevrengDanske Bank
Ludvig SvenssonPenser Access